Enzo Biochem (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.

Enzo Biochem, Inc. reported improved sequential results for the first fiscal quarter ended October 31, 2010, the result of recent programs to reduce expenses, consolidate activities and expand operations.

“We are pleased to report that our program instituted this quarter aimed at making Enzo more efficient and designed to produce more effective use of our assets is beginning to show results, as demonstrated by improved performance, ” said Barry Weiner, President. “While we are in the early stages of this comprehensive program, the results experienced to date are very encouraging.”

Among the quarter's highlights (all references are to sequential quarter over quarter results, normalized for an inventory charge and severance of $1.8 million where applicable):

* Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
* Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
* Company-wide, gross margin increased $2.0 million or 17%.
* Operating expenses decreased 7%, or to 57% of revenues, from 63%.
* EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
* Net loss for the quarter was reduced 70%.

Enzo Therapeutics: Leading the development of medicines based on genetic and immune regulation to combat infectious diseases, autoimmune-based diseases and cancers.

Enzo Life Sciences is a leading manufacturer of high quality reagents, kits and products supplied to scientific researchers in academia, clinical research and drug discovery. With direct sales operations in US, Switzerland, Germany, UK, France and Benelux, Enzo Life Sciences also supports its 8000 products through a global network of dedicated distributors.

Enzo Clinical Labs is much more than a highly respected clinical laboratory. Enzo Clinical Labs is utilized extensively to demonstrate the benefits of gene-based products developed at Enzo Life Sciences. It also plays an important role in the development of and performance of tests used to support the on going trials of Enzo Therapeutics.

**********************************************

Lawson Software, Inc. (Nasdaq:LWSN) announced it will release its fiscal 2011 second quarter financial results on Thursday, Jan. 6, 2011, after the market closes. The company will host a webcast and conference call to discuss its second quarter results and future outlook at 5 p.m. EDT (4 p.m. CDT) Jan. 6, 2011. A live webcast will be available at 5 p.m. EDT (4 p.m. CDT) Jan. 6, 2011. Interested parties may also listen to the call by dialing 1-888-810-4935 (or 1-312-470-0073) and using the passcode “LWSN.” Interested parties should access the webcast or dial into the conference call approximately 10-15 minutes before the scheduled start time.

Lawson Software is a global provider of enterprise software. We provide business application software, maintenance and consulting to customers primarily in specific services, trade and manufacturing/distribution industries.

**********************************************

Halozyme Therapeutics, Inc. (Nasdaq:HALO) announced that Roche has completed patient enrollment for the pivotal Phase 3 study of Herceptin SC (trastuzumab subcutaneous), a subcutaneous formulation that uses Halozyme's Enhanze™ technology (rHuPH20, recombinant human hyaluronidase). Patients in the study receive chemotherapy concurrent with either Herceptin intravenous (IV) or Herceptin SC every three weeks for the first 8 cycles. Herceptin is approved to treat HER2-positive breast and gastric cancer and currently is given intravenously over 30 to 90 minutes.

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets.

**********************************************

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that it received the Licensing Deal of the Year award from Scrip Intelligence at the Sixth Annual Scrip Awards last month. The Award, presented jointly to Rigel and AstraZeneca, recognizes the significance of the collaboration forged by the companies to develop fostamatinib (previously referred to as R788) as a novel oral treatment for rheumatoid arthritis (RA). This is the first award of its kind given by Scrip to acknowledge the vital importance of licensing to the pharmaceutical industry's R&D strategies.

Rigel granted AstraZeneca exclusive rights to the future development and commercialization of fostamatinib.

**************************************************************

********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.